• CAS
  • |
  • C&EN
  • |
  • Journals
  • |
  • ACS

search site
Advanced Search »
  • Home
  • |
  • About CAS
    • 100th Anniversary Celebration
    • CAS Quotes
    • Colors of Chemistry
    • Careers at CAS
    • Contact Us
    • Directions to CAS
    • FAQs
  • |
  • Our Expertise
    • CAS Databases
    • Value Added Tools
    • Technical Service and Support
  • |
  • Solutions
    • Researchers
    • IP Professionals
    • Information Professionals
    • Academics
  • |
  • Products & Services
    • SciFinder
    • SciFinder Scholar
    • STN Family of Products
    • Science IP
    • CAS Client Services
    • CAS Document Detective Service
    • CD Products
    • Print Products
  • |
  • Support & Training
    • SciFinder
    • SciFinder Scholar
    • STN
    • STN Express
    • STN AnaVist
    • STN Viewer
    • STN on the Web
    • STN Easy
    • CAS Customer Care
  • |
  • News & Events
    • What's New
    • Press Room
    • News Releases
    • In the News
    • Trade Shows
  • CAS Science Spotlight Home
  • Most Cited Patent Families 2000-Chemistry and Related
  • About
  • What's New
Home   •   Spotlight  •  pcite00  •  Most Cited Patent Families 2000-Chemistry and Related (9)
Most Cited Patent Families 2000-Chemistry and Related

spotlightlogo.gif

Following is a CAS database record representing a highly cited patent family.


CAS indexed 52 chemical substances from this document.
CAS subject entries for this document include: Antiarteriosclerotics; Anticholesteremic agents; Antidiabetic agents; and 5 additional concepts.

CAPLUS COPYRIGHT 2001 ACS

TITLE: Preparation of benzimidazolylalkoxyarenes for treatment of hyperlipemia, hyperglycemia, obesity, impaired glucose tolerance, insulin resistance, and diabetic complications.
INVENTOR(S): Fujita, Takashi; Wada, Kunio; Oguchi, Minoru; Yanagisawa, Hiroaki; Fujimoto, Koichi; Fujiwara, Toshihiko; Horikoshi, Hiroyoshi; Yoshioka, Takao
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 227 pp. CODEN: EPXXDW
LANGUAGE: English
PATENT INFORMATION:
PATENT NO.       KIND  DATE           APPLICATION NO.  DATE
---------------  ----  --------       ---------------  --------
EP 745600         A1   19961204       EP 1996-303940   19960531
	 R:  AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL,
	     PT, SECA 2177858        AA   19961202       CA 1996-2177858  19960531
NO 9602239        A    19961202       NO 1996-2239     19960531
ZA 9604518        A    19961209       ZA 1996-4518     19960531
AU 9654627        A1   19961212       AU 1996-54627    19960531
AU 712390         B2   19991104
JP 09295970       A2   19971118       JP 1996-137930   19960531
JP 2976885        B2   19991110
RU 2125048        C1   19990120       RU 1996-110410   19960531
JP 2000001487     A2   20000107       JP 1999-150312   19960531
CN 1157288        A    19970820       CN 1996-110937   19960601

ABSTRACT:
Title compds. [I; X = (substituted) benzimidazolyl; Y = O, S; Z = 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxo-oxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl, CH2N(OH)CONH2; R = H, alkyl, alkoxy, halo, OH, NO2, amino, aralkyl; m = 1-5], were prepd. Thus, N-methyl-1,2-phenylenediamine and 5-[4-(ethoxycarbonylmethoxy)benzyl]thiazolidine-2,4-dione (prepn. given) were refluxed 5 h in aq. HCl/dioxane to give 5-[4-(1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione. The latter at 5 .mu.g/mL gave 80.3% inhibition of bovine lens aldose reductase.

View full-text pdf document from MicroPatent, a participating ChemPort patent provider.

Updated 8/1/2007 9:20:24 AM
Home  |  About CAS  |  Our Expertise  |  Solutions  |  Products & Services  |  Support  |  News & Events
Copyright © 2008 American Chemical Society